Little Lion Biotechnologies Inc., the surviving entity of a merger earlier this year with Genesis Biopharma Inc., reported promising long-term findings from a Phase II trial in Stage IV metastatic melanoma. The study was conducted by the National Cancer Institute (NCI) using tumor-infiltrating lymphocyte (TIL) technology licensed by the company and in development under a five-year Cooperative Research and Development Agreement that Genesis inked with the Institute in 2011.